Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

Related Articles by Review for PubMed (Select 21920711)

1.

Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.

Friedman ES, Davis LL, Zisook S, Wisniewski SR, Trivedi MH, Fava M, Rush AJ; CO-MED Study Team.

Eur Neuropsychopharmacol. 2012 Mar;22(3):183-99. doi: 10.1016/j.euroneuro.2011.07.010. Epub 2011 Sep 14.

2.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
3.
4.

[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].

Gourion D.

Encephale. 2008 Jan;34(1):73-81. doi: 10.1016/j.encep.2007.12.001. Epub 2008 Feb 5. Review. French.

PMID:
18514154
5.

Evidence of early onset of antidepressant effect in randomized controlled trials.

Stahl SM, Nierenberg AA, Gorman JM.

J Clin Psychiatry. 2001;62 Suppl 4:17-23; discussion 37-40. Review.

PMID:
11229783
6.

An overview of the clinical efficacy of mirtazapine.

Benkert O, Muller M, Szegedi A.

Hum Psychopharmacol. 2002 Jun;17 Suppl 1:S23-6. Review.

PMID:
12404666
7.

[Escitalopram for treatment of major depressive disorder in adults].

Llorca PM, Brousse G, Schwan R.

Encephale. 2005 Jul-Aug;31(4 Pt 1):490-501. Review. French.

PMID:
16389716
8.

Severe depression: is there a best approach?

Sonawalla SB, Fava M.

CNS Drugs. 2001;15(10):765-76. Review.

PMID:
11602003
9.

A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Renaud J, Axelson D, Birmaher B.

Drug Saf. 1999 Jan;20(1):59-75. Review.

PMID:
9935277
10.

Management of treatment-resistant depression in children and adolescents.

DeFilippis M, Wagner KD.

Paediatr Drugs. 2014 Oct;16(5):353-61. doi: 10.1007/s40272-014-0088-y. Review.

PMID:
25200567
11.

[Folates in the treatment of depression].

Erbe S, Pellert UN.

Fortschr Neurol Psychiatr. 2014 Feb;82(2):78-83. doi: 10.1055/s-0033-1356123. Epub 2014 Feb 11. Review. German.

PMID:
24519190
12.

CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?

Macaluso M, Preskorn SH.

J Clin Psychopharmacol. 2011 Apr;31(2):143-5. doi: 10.1097/JCP.0b013e318212d7cb. Review. No abstract available.

PMID:
21346604
13.

[Venlafaxine (velaxin) effectivity in treatment of depression: results of the recent investigations].

Veltishchev DY.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(11 Pt 2):79-81. Review. Russian. No abstract available.

PMID:
24429970
14.

Novel antidepressant drugs, arterial hypertension and cardiovascular disease.

Katsi VK, Marketou M, Vamvakou G, Makris T, Tousoulis D, Stefanadis CI, Vardas P, Kallikazaros IE.

Recent Pat Cardiovasc Drug Discov. 2013 Dec;8(3):178-85. Review.

PMID:
24712681
15.

α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy.

Cottingham C, Wang Q.

Neurosci Biobehav Rev. 2012 Nov;36(10):2214-25. doi: 10.1016/j.neubiorev.2012.07.011. Epub 2012 Aug 13. Review.

16.

Restoring trust in the pharmaceutical sector on the basis of the SSRI case.

Hernandez JF, van Thiel GJ, Mantel-Teeuwisse AK, Raaijmakers JA, Pieters T.

Drug Discov Today. 2014 May;19(5):523-7. doi: 10.1016/j.drudis.2013.11.019. Epub 2013 Dec 1. Review.

PMID:
24295641
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk